Feb 21 |
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
|
Feb 5 |
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
|
Jan 26 |
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
|
Jan 19 |
ChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To Profit
|
Nov 28 |
An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 44% Undervalued
|
Nov 15 |
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
|
Nov 7 |
ChromaDex Q3 2023 Earnings Preview
|
Nov 1 |
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
|
Oct 31 |
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
|